Oct 2026
FAP-targeted [177Lu]Lu-FAP-2286 radioligand therapy synergizes with the STING agonist diABZI to enhance antitumor immunity in lung cancer.
This combination reshapes the tumor immune microenvironment via enhanced CD8+ T-cell infiltration and IFN-β-mediated immune activation and IFN-β-mediated immune activation, offering a translatable strategy for patients with advanced FAP-expressing lung cancer.
Jia-Hao Xie, Yi-Jin Zou, Da-Zhi Shi et al.
· Nuclear Medicine and Biology · 0 citations